<DOC>
	<DOCNO>NCT00938613</DOCNO>
	<brief_summary>The primary objective study compare relative efficacy Budesonide administer via Captisol-Enabled Budesonide nasal solution Rhinocort Aqua patient seasonal allergic rhinitis ( SAR ) expose control ragweed pollen use EEC model .</brief_summary>
	<brief_title>Compare CE-Budesonide Nasal Solution &amp; Rhinocort Aqua EEC Study AR</brief_title>
	<detailed_description>A Randomized , Double-Blind , Placebo-Controlled , Single-Center , Three-Way Cross-Over Study Compare Relative Efficacy Budesonide administer via Captisol-Enabled® Budesonide Nasal Solution Rhinocort Aqua® ( 32 µg/spray ) Treatment Symptoms Allergic Rhinitis Environmental Exposure Chamber ( EEC ) .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Patients must clinical history SAR Adults ( male female ) age 18 65 , inclusive Patients must documentation positive skin test within 12 month screen ragweed allergen Nonpregnant , nonlactating female , woman postmenopausal naturally surgically sterile . Females childbearing potential must confirm absence pregnancy must use acceptable birth control method In generally good health Willingness attend study visit Capable follow understanding instruction Willing able provide write informed consent prior initiation study procedure , include initiation washout concomitant medication Pregnancy , nursing , plan become pregnant donate gamete Have clinically significant physical finding nasal anatomical deformity cause great 50 % obstruction Previous participation budesonide study within three month prior Screening Visit . Participation investigational drug trial within 30 day precede Screening Visit , thereafter . A known hypersensitivity corticosteroid excipients formulation investigational drug History severe respiratory infection disorder History alcohol drug abuse History positive test HIV , hepatitis B hepatitis C. Active asthma require treatment inhale systemic corticosteroid and/or routine use ßagonists controller drug , intermittent use ( less equal 3 us per week ) inhale short act ßagonists acceptable . Use prohibit medication within identify exclusion period Use antibiotic therapy acute condition within 14 day prior Screening Visit thereafter . Low dos antibiotic take prophylaxis permit base judgment Investigator therapy start prior Screening Visit AND expect continue throughout study . Initiation immunotherapy dose escalation study period . However , patient may consider inclusion immunotherapy initiate 90 day prior Screening Visit AND dose stable ( maintenance dose ) 30 day prior Screening Visit . No immunotherapy injection may receive within 48 hour prior ragweed pollen exposure visit . Nonvaccinated exposure active infection chickenpox measles within 21 day precede Screening Visit . Exposure systemic corticosteroid indication , chronic intermittent ( e.g. , arthritis ) , 60 day precede Screening Visit , presence underlying condition reasonably expect require treatment corticosteroid course study . Use topical corticosteroid concentration excess 1 % hydrocortisone equivalent dermatological condition within 30 day prior Screening Visit History epilepsy seizures History coronary heart disease , uncontrolled hypertension , clinically significant cardiovascular disease . Have follow condition judge investigator clinically significant and/or affect patient 's ability participate clinical trial : Impaired hepatic function include alcohol relate liver disease cirrhosis History ocular disturbance ( e.g. , glaucoma posterior subcapsular cataract ) Any systemic infection Hematological , renal , endocrine ( except control diabetes mellitis postmenopausal symptom hypothyroidism ) Gastrointestinal disease Malignancy ( exclude basal cell carcinoma ) A current neuropsychiatric condition without drug therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>SAR</keyword>
</DOC>